Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Pooled Analysis Shows Maintenance Therapy Improves Survival in Multiple Myeloma

Though previous studies have indicated prolonged progression-free survival (PFS) with maintenance therapy in patients with multiple myeloma (MM), experts disagree about its effect on...
On location

Autologous Transplant Improves Complete Response, Disease Control in Patients Treated with Carfilzomib-Based Combo

In a phase I/II trial of patients with newly diagnosed multiple myeloma (MM), 55 percent of patients treated with the combination of carfilzomib, lenalidomide,...
On location

Results from a Phase II Study of Crenolanib in Patients With FLT3-Positive Acute Myeloid...

CHICAGO--The next-generation tyrosine kinase inhibitor (TKI) crenolanib besylate showed “encouraging” activity and safety as a single agent in patients with relapsed/refractory FLT3-positive acute myeloid...
On location

CLL-IPI: A New and Improved Staging System for CLL?

In a recent study examining the validity of prognostic markers for patients with chronic lymphocytic leukemia (CLL), researchers believe they have developed an internationally...
On location

Study Finds Idarucizumab Can Reverse the Anticoagulant Effects of Dabigatran

The experimental drug idarucizumab quickly and effectively reversed the anticoagulant effect of dabigatran within minutes, according to results from an interim analysis presented at...

Pacritinib Leads to Better Symptom Control, Improved Cytopenias in Myelofibrosis

Compared with other available treatments, the JAK2 inhibitor pacritinib leads to more effective spleen volume reduction and better symptom control in patients with myelofibrosis,...
On location

For Occult Cancer in VTE Patients, Routine Screening Is Enough

For the more than 500,000 Americans and Canadians who are diagnosed with unprovoked venous thromboembolism (VTE) each year, VTE may be an early sign...
On location

Study Finds Clinical Benefit for ERY001 in ALL

Asparaginase is a commonly prescribed treatment option for acute lymphocytic leukemia (ALL), but its use can be limited by its toxicities, including drug hypersensitivity....
On location

The DNMT3A R882 Mutation’s Impaired DNA-Damage Sensing: A Key to Overcoming Chemoresistance in AML

A study presented at the 2015 European Hematology Association Congress suggests an important role for DNMT3A R882 mutations in chemoresistance in acute myeloid leukemia...
On location

Early Trials in AML and CMML Offer Promising Results

In early-phase trials conducted in patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), two investigational agents (ASP2215 and CPI-613) and one...
Advertisement

Current Issue

September 2020 Volume 6, Issue 11

This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.

Block title